24 Jan 2021
|
Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration
|
|
20 Jan 2021
|
FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
|
|
04 Jan 2021
|
Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer
|
|
20 Dec 2020
|
Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
|
|
14 Dec 2020
|
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
|
neuroscience
|
05 Dec 2020
|
Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic Lymphocytic Leukemia
|
|
01 Dec 2020
|
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
|
|
01 Dec 2020
|
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
|
|
23 Nov 2020
|
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
|
|
05 Nov 2020
|
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
|
|
16 Oct 2020
|
Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia
|
|
27 Sep 2020
|
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
|
|
19 Sep 2020
|
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
|
|
17 Sep 2020
|
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
|
|
10 Sep 2020
|
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
|
neuroscience
|
09 Sep 2020
|
New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum DIsorder
|
neuroscience
|
08 Sep 2020
|
Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)
|
neuroscience
|
04 Sep 2020
|
Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
|
|
02 Sep 2020
|
Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020
|
neuroscience
|
18 Aug 2020
|
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
|
|
14 Aug 2020
|
FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder
|
neuroscience
|
12 Aug 2020
|
FDA Accepts Application for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across all Indications
|
|
09 Aug 2020
|
Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis
|
|
07 Aug 2020
|
FDA Approves Genentech’s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older
|
neuroscience
|
06 Aug 2020
|
Genentech Provides Update On Phase III Study Of Tecentriq In Combination With Paclitaxel For People With Metastatic Triple-Negative Breast Cancer
|
|
30 Jul 2020
|
FDA Approves Genentech’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma
|
|
28 Jul 2020
|
Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia
|
|
22 Jul 2020
|
Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration
|
|
12 Jul 2020
|
Genentech Provides Update on Phase III Study of Tecentriq in Women With Advanced-Stage Ovarian Cancer
|
|
12 Jul 2020
|
New Data From Phase IIIb Study Reinforces Safety Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Hemophilia A
|
|
29 Jun 2020
|
FDA Approves Genentech’s Phesgo (Fixed-Dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-Positive Breast Cancer
|
|
18 Jun 2020
|
Genentech’s IPATential150 Study Evaluating Ipatasertib in Combination With Abiraterone and Prednisone/Prednisolone Met One of Its Co-Primary Endpoints
|
|
17 Jun 2020
|
Genentech’s Tecentriq in Combination With Chemotherapy (Including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer
|
|
12 Jun 2020
|
Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults With Spinal Muscular Atrophy (SMA)
|
neuroscience
|
12 Jun 2020
|
Positive Phase III Results for Venclexta Combination in Acute Myeloid Leukemia Presented at EHA 2020
|
|
29 May 2020
|
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
|
|
27 May 2020
|
Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
|
|
26 May 2020
|
Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
|
|
21 May 2020
|
New Longer-Term Data Reinforce Safety of Genentech’s Satralizumab in Adults and Adolescents With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
neuroscience
|
18 May 2020
|
FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer
|
|
13 May 2020
|
Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO
|
|
10 May 2020
|
Changes to the Roche Enlarged Corporate Executive Committee
|
|
06 May 2020
|
New Data at the ASCO20 Virtual Scientific Program Reflects Genentech’s Commitment to Accelerating Progress in Cancer Care
|
|
27 Apr 2020
|
Genentech’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA)
|
neuroscience
|
27 Apr 2020
|
New 6-Year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis
|
neuroscience
|
19 Apr 2020
|
FDA and EMA Accept Applications for Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time
|
neuroscience
|
07 Apr 2020
|
Genentech Provides Regulatory Update on Risdiplam for the Treatment of Spinal Muscular Atrophy (SMA)
|
neuroscience
|
26 Mar 2020
|
FDA Accepts Genentech’s New Drug Application for Xofluza for the Treatment of Influenza In Children
|
|
23 Mar 2020
|
Genentech Announces Venclexta Combination Improved Overall Survival in People With Previously Untreated Acute Myeloid Leukemia
|
|
23 Mar 2020
|
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
|
|
18 Mar 2020
|
Genentech Initiates Phase III Clinical Trial Of Actemra In Hospitalized Patients With Severe COVID-19 Pneumonia
|
|
02 Mar 2020
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Esbriet (pirfenidone) in Unclassifiable Interstitial Lung Disease
|
|
24 Feb 2020
|
FDA Accepts Genentech’s Biologics License Application for Fixed-Dose Subcutaneous Combination of Perjeta And Herceptin For HER2-Positive Breast Cancer
|
|
18 Feb 2020
|
FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-Line Treatment of Certain People With Advanced Non-Small Cell Lung Cancer
|
|
09 Feb 2020
|
Genentech Provides Topline Results From Investigator-Led Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer’s Disease
|
neuroscience
|
06 Feb 2020
|
Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 With Type 2 or 3 Spinal Muscular Atrophy
|
neuroscience
|
26 Jan 2020
|
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
|
|
23 Jan 2020
|
Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-Invasive Urothelial Cancer
|
|
22 Jan 2020
|
Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy
|
neuroscience
|
12 Dec 2019
|
Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
|
|
11 Dec 2019
|
Genentech’s Fixed-dose Subcutaneous Combination of Perjeta and Herceptin Comparable to Intravenous Formulations in People With HER2-Positive Breast Cancer
|
|
10 Dec 2019
|
FDA Accepts Supplemental Biologics License Application for Xolair (Omalizumab) for the Treatment of Nasal Polyps
|
|
08 Dec 2019
|
New Data Demonstrate the Continued Clinical Benefit of Fixed-duration, Chemotherapy-free Venclexta-based Treatments in Chronic Lymphocytic Leukemia
|
|
07 Dec 2019
|
Genentech Announces New Data on Novel CD20-CD3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas
|
|
03 Dec 2019
|
FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
|
|
01 Dec 2019
|
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
|
neuroscience
|
24 Nov 2019
|
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
|
neuroscience
|
22 Nov 2019
|
Genentech Presents Pivotal Data Demonstrating Tecentriq in Combination With Avastin Improves Overall Survival in People With the Most Common Form of Liver Cancer
|
|
17 Nov 2019
|
Genentech to Present New and Updated Data for Seven Approved and Investigational Medicines Across Multiple Types of Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
|
|
10 Nov 2019
|
Genentech’s Risdiplam Meets Primary Endpoint In Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy
|
neuroscience
|
09 Nov 2019
|
Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared To Standard of Care Alone
|
|
06 Nov 2019
|
Genentech to Present New Data Highlighting Breadth of Hematology Portfolio and Pipeline at the American Society of Hematology 2019 Annual Meeting
|
|
29 Oct 2019
|
FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
|
neuroscience
|
20 Oct 2019
|
Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-Free Survival in People With Unresectable Hepatocellular Carcinoma
|
|
17 Oct 2019
|
Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
|
|
13 Oct 2019
|
Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
|
|
30 Sep 2019
|
Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-Based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
|
|
29 Sep 2019
|
Genentech to Present Results of First Prospective Trial Using Blood-Based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib)
|
|
27 Sep 2019
|
Genentech’s Tecentriq (Atezolizumab) Improves Overall Survival as a First-Line Monotherapy in Certain People With Advanced Non-Small Cell Lung Cancer
|
|
27 Sep 2019
|
FDA Approves Genentech’s Rituxan (Rituximab) in Children With Two Rare Blood Vessel Disorders
|
|
17 Sep 2019
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis
|
|
12 Sep 2019
|
Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
|
neuroscience
|
12 Sep 2019
|
Genentech’s Fixed Dose Subcutaneous Combination of Perjeta And Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer
|
|
11 Sep 2019
|
Genentech’s Tecentriq (Atezolizumab) as a First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy
|
|
11 Sep 2019
|
Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder
|
neuroscience
|
09 Sep 2019
|
Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple Sclerosis at ECTRIMS
|
neuroscience
|
03 Sep 2019
|
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-Year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
|
neuroscience
|
01 Sep 2019
|
Genentech Presents Positive Phase III Study Results for One-Dose Xofluza (Baloxavir Marboxil) in Children With the Flu
|
|
01 Sep 2019
|
Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent
|
|
15 Aug 2019
|
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
|
|
04 Aug 2019
|
Genentech’s Tecentriq® (Atezolizumab) Plus Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
|
|
08 Jul 2019
|
Genentech Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits for People With Hemophilia A at the ISTH 2019 Congress
|
|
02 Jul 2019
|
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
|
|
12 Jun 2019
|
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
|
|
11 Jun 2019
|
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children With Two Rare Blood Vessel Disorders
|
|
10 Jun 2019
|
FDA Grants Genentech’s Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma
|
|
10 Jun 2019
|
Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
|
|
04 Jun 2019
|
Pivotal Phase III CLL14 Results for Venclexta in Combination With Gazyva for Chronic Lymphocytic Leukemia Presented at ASCO 2019 and Published in the New England Journal of Medicine
|
|
03 Jun 2019
|
Phase III Study Showed XOFLUZA (Baloxavir Marboxil) is Effective at Preventing Influenza Infection
|
|
02 Jun 2019
|
Xolair (omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults With Chronic Rhinosinusitis With Nasal Polyps in Two Phase III Studies
|
|
15 May 2019
|
Genentech Announces FDA Approval for Venclexta plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia
|
|
15 May 2019
|
Genentech’s Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, ROS1 Or ALK Gene Fusions in Children and Adolescents
|
|
09 May 2019
|
Genentech to Present New Data Highlighting Comprehensive Approach to Cancer Care at 2019 American Society Of Clinical Oncology (ASCO) Annual Meeting
|
|
07 May 2019
|
Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Relapsing and Primary Progressive Multiple Sclerosis at the AAN Annual Meeting
|
neuroscience
|
06 May 2019
|
Genentech Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studies in Spinal Muscular Atrophy at the 2019 AAN Annual Meeting
|
neuroscience
|
03 May 2019
|
FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
|
|
28 Apr 2019
|
New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
|
neuroscience
|
18 Mar 2019
|
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
|
|
08 Mar 2019
|
FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
|
|
07 Mar 2019
|
Genentech Submits Supplemental New Drug Application to FDA for Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukemia with Co-Existing Medical Conditions
|
|
05 Mar 2019
|
FDA Accepts Genentech’s Supplemental New Drug Application for Xofluza (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications
|
|
28 Feb 2019
|
FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers
|
|
18 Feb 2019
|
FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma
|
|
18 Feb 2019
|
FDA Grants Priority Review to Genentech’s Personalized Medicine Entrectinib
|
|
04 Feb 2019
|
Genentech Submits Supplemental Biologics License Application to FDA For Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
29 Jan 2019
|
Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue
|
neuroscience
|
16 Jan 2019
|
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
|
|
06 Dec 2018
|
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
|
|
05 Dec 2018
|
Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
04 Dec 2018
|
FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer
|
|
03 Dec 2018
|
Genentech’s Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors
|
|
03 Dec 2018
|
New Venclexta® Data Demonstrate Deep Responses in Two of the Most Common Types of Leukemia
|
|
26 Nov 2018
|
FDA Approves The ACTpen For Genentech’s ACTEMRA, A Single-Dose, Prefilled Autoinjector For The Treatment Of Rheumatoid Arthritis, Giant Cell Arteritis And Two Forms Of Juvenile Arthritis
|
|
21 Nov 2018
|
Genentech Announces FDA Grants Venclexta Accelerated Approval for People With Newly-Diagnosed Acute Myeloid Leukemia or Those Who Are Ineligible For Intensive Induction Chemotherapy
|
|
12 Nov 2018
|
FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
|
|
01 Nov 2018
|
Genentech to Present New Data From Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting
|
|
31 Oct 2018
|
Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
|
|
27 Oct 2018
|
New STAIRWAY Study Data Shows Potential for Extended Durability With Faricimab in Wet Age-Related Macular Degeneration (AMD)
|
|
24 Oct 2018
|
Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza
|
|
22 Oct 2018
|
Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
|
|
21 Oct 2018
|
Genentech’s Investigational Personalized Medicine Entrectinib Shrank Tumors in People With NTRK Fusion-Positive Solid Tumors
|
|
20 Oct 2018
|
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
|
|
19 Oct 2018
|
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
|
|
14 Oct 2018
|
Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
09 Oct 2018
|
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
|
neuroscience
|
08 Oct 2018
|
Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and Across a Wide Range of Cancers at The European Society for Medical Oncology (ESMO) 2018 Congress
|
|
04 Oct 2018
|
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors
|
|
03 Oct 2018
|
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
|
neuroscience
|
03 Oct 2018
|
Positive Phase III Results for Baloxavir Marboxil in People at High Risk of Complications From Influenza to be Presented at IDWeek 2018
|
|
01 Oct 2018
|
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
|
neuroscience
|
28 Sep 2018
|
FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation
|
|
25 Sep 2018
|
Genentech’s TECENTRIQ in Combination With Chemotherapy Helped People Live Significantly Longer as an Initial Treatment for People With Extensive-Stage Small Cell Lung Cancer
|
|
24 Sep 2018
|
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung Cancer
|
|
24 Sep 2018
|
Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer
|
|
13 Sep 2018
|
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
|
|
05 Sep 2018
|
Genentech to Present New Data from Its Extensive Lung Cancer Program at the 2018 World Conference on Lung Cancer (WCLC)
|
|
29 Aug 2018
|
Positive Phase III Results for Genentech’s HEMLIBRA® (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine
|
|
12 Aug 2018
|
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
|
|
25 Jul 2018
|
Genentech Unveils Positive Phase II Results for the Port Delivery System with Ranibizumab (PDS), the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
|
|
19 Jul 2018
|
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)
|
neuroscience
|
18 Jul 2018
|
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer
|
|
17 Jul 2018
|
FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
|
16 Jul 2018
|
Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
|
|
11 Jul 2018
|
Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
|
|
01 Jul 2018
|
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
|
|
25 Jun 2018
|
FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza
|
|
24 Jun 2018
|
Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy
|
|
13 Jun 2018
|
FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
|
|
13 Jun 2018
|
Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
|
neuroscience
|
08 Jun 2018
|
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
|
|
07 Jun 2018
|
FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
|
|
04 Jun 2018
|
FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxwh) for People With Hemophilia A Without Factor VIII Inhibitors
|
|
02 Jun 2018
|
Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer
|
|
28 May 2018
|
Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
|
|
20 May 2018
|
Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors
|
|
16 May 2018
|
Follow-Up Phase III Data Showed Genentech’s Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death
|
|
16 May 2018
|
Phase III IMpower150 Study Showed Genentech's TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
|
|
14 May 2018
|
FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), a Rare Form of Juvenile Arthritis
|
|
13 May 2018
|
Genentech to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in People With Hemophilia A at the World Federation of Hemophilia 2018 World Congress
|
|
09 May 2018
|
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
|
|
07 May 2018
|
Genentech to Present New Data From Its Industry-Leading Oncology Portfolio at The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
06 May 2018
|
FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for Initial Treatment of People With a Specific Type of Metastatic Lung Cancer
|
|
22 Apr 2018
|
New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
|
neuroscience
|
16 Apr 2018
|
FDA Grants Breakthrough Therapy Designation For Genentech’s HEMLIBRA (emicizumab-kxwh) in Hemophilia A Without Inhibitors
|
|
15 Apr 2018
|
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
|
neuroscience
|
25 Mar 2018
|
Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Plus Carboplatin and Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared to Avastin Plus Carboplatin and Paclitaxel
|
|
21 Mar 2018
|
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
|
|
19 Mar 2018
|
Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced The Risk of Disease Worsening or Death in the Initial Treatment of People With a Type of Advanced Squamous Lung Cancer
|
|
13 Feb 2018
|
FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris
|
|
11 Feb 2018
|
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
|
|
05 Feb 2018
|
Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People with Advanced Kidney Cancer
|
|
20 Dec 2017
|
FDA Approves Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
|
|
12 Dec 2017
|
Genentech Announces Phase III Data Showing Venclexta plus Rituxan Reduced the Risk of Disease Progression or Death by 83 Percent Compared to a Standard of Care Regimen in Previously Treated Chronic Lymphocytic Leukemia
|
|
10 Dec 2017
|
Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma
|
|
10 Dec 2017
|
Phase III IMmotion151 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
|
|
09 Dec 2017
|
Genentech’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduce Bleeds in People with Hemophilia A with Inhibitors
|
|
06 Dec 2017
|
Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
|
|
06 Dec 2017
|
Phase III IMpower150 Study Showed Tecentriq (atezolizumab) and Avastin (bevacizumab) Plus Chemotherapy Reduced the Risk of Disease Worsening or Death by 38 Percent for People with a Type of Advanced Lung Cancer
|
|
05 Dec 2017
|
FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer
|
|
04 Dec 2017
|
First “Cancer Screen Week” Calls on Americans to Act Now Against Cancer by Taking Pledge to Get Screened
|
|
19 Nov 2017
|
Phase III IMpower150 Study Showed Genentech’s Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung Cancer
|
|
19 Nov 2017
|
Genentech’s Hemlibra (Emicizumab-kxwh) Significantly Reduced Bleeds in Phase III Study in Hemophilia A
|
|
16 Nov 2017
|
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors
|
|
16 Nov 2017
|
FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
|
|
06 Nov 2017
|
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
|
|
06 Nov 2017
|
FDA Approves Genentech’s Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer
|
|
01 Nov 2017
|
Genentech to Present New Data Across a Range of Blood Diseases at The American Society of Hematology (ASH) 2017 Annual Meeting
|
|
26 Oct 2017
|
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
|
neuroscience
|
25 Oct 2017
|
FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women with Advanced Ovarian Cancer
|
|
15 Oct 2017
|
Genentech to Present New Ocrevus (Ocrelizumab) Efficacy & Safety Data in Relapsing and Primary Progressive Forms of Multiple Sclerosis at ECTRIMS
|
neuroscience
|
28 Sep 2017
|
FDA Grants Priority Review for Genentech’s Perjeta® (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer
|
|
18 Sep 2017
|
Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic Lymphocytic Leukemia Live Longer Without Their Disease Worsening Compared to Bendamustine Plus Rituxan
|
|
08 Sep 2017
|
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
|
|
06 Sep 2017
|
Genentech Issues Voluntary Nationwide Recall of Three Lots of Activase® (Alteplase)-100 mg Due to Lack of Sterility Assurance of the Sterile Water for Injection
|
|
30 Aug 2017
|
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
|
|
27 Aug 2017
|
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
|
|
23 Aug 2017
|
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
|
|
07 Aug 2017
|
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
|
|
02 Aug 2017
|
FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer
|
|
26 Jul 2017
|
Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine
|
|
10 Jul 2017
|
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
|
|
25 Jun 2017
|
Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors
|
|
22 Jun 2017
|
FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers
|
|
22 Jun 2017
|
New Data at EAN Show Genentech’s Ocrevus (Ocrelizumab) Significantly Reduced Multiple Measures of Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis
|
neuroscience
|
05 Jun 2017
|
APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer
|
|
05 Jun 2017
|
Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer
|
|
22 May 2017
|
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
|
|
10 May 2017
|
Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
09 May 2017
|
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
|
|
25 Apr 2017
|
New Data at AAN Reinforce Clinical Benefit of Genentech’s Ocrevus (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis
|
neuroscience
|
18 Apr 2017
|
Genentech to Present New Data at AAN Reinforcing Efficacy And Safety of Newly FDA Approved Ocrevus (Ocrelizumab) in Two Types of Multiple Sclerosis
|
neuroscience
|
17 Apr 2017
|
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
|
|
17 Apr 2017
|
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States
|
|
16 Apr 2017
|
Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A
|
|
09 Apr 2017
|
Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer
|
|
29 Mar 2017
|
FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers
|
|
28 Mar 2017
|
FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
|
neuroscience
|
23 Mar 2017
|
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
|
|
01 Mar 2017
|
Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer without their Disease Returning Compared to Herceptin® and Chemotherapy
|
|
17 Feb 2017
|
Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People with Locally Advanced or Metastatic Renal Cell Carcinoma
|
|
23 Jan 2017
|
FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis
|
|
08 Jan 2017
|
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
|
|
05 Jan 2017
|
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
|
|
21 Dec 2016
|
Positive Phase III Results of Genentech’s Investigational Medicine Ocrevus™ (Ocrelizumab) Published in New England Journal of Medicine
|
neuroscience
|
21 Dec 2016
|
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
|
|
20 Dec 2016
|
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
|
neuroscience
|
06 Dec 2016
|
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
|
|
04 Dec 2016
|
Genentech’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer without their Disease Worsening Compared to Rituxan
|
|
12 Nov 2016
|
Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis
|
|
03 Nov 2016
|
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
|
|
01 Nov 2016
|
Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
|
|
18 Oct 2016
|
FDA Approves Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer
|
|
14 Oct 2016
|
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
|
|
10 Oct 2016
|
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
|
|
08 Oct 2016
|
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy Regardless of PD-L1 Status in a Specific Type of Lung Cancer in Phase III Study
|
|
04 Oct 2016
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
|
|
03 Oct 2016
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
|
|
13 Sep 2016
|
Phase III Efficacy Results of Investigational Medicine Ocrevus™ (Ocrelizumab) Reinforced by Exploratory Analyses in Two Forms of Multiple Sclerosis
|
neuroscience
|
31 Aug 2016
|
Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy
|
|
17 Jul 2016
|
Genentech Provides Update on Phase III Study of Gazyva® in People with Previously Untreated Diffuse Large B-Cell Lymphoma
|
|
07 Jul 2016
|
FDA Approves Genentech’s Xolair® (omalizumab) for Allergic Asthma in Children
|
|
27 Jun 2016
|
FDA Grants Priority Review for Genentech’s OCREVUS™ (Ocrelizumab) Biologics License Application
|
neuroscience
|
05 Jun 2016
|
Genentech’s Cancer Immunotherapy Tecentriq™ (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
|
|
05 Jun 2016
|
Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis (GCA)
|
|
26 May 2016
|
Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma
|
|
18 May 2016
|
FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer
|
|
18 May 2016
|
Phase III Study of Genentech’s Alecensa® (alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People with a Specific Type of Lung Cancer
|
|
02 May 2016
|
Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
12 Apr 2016
|
Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
|
neuroscience
|
11 Apr 2016
|
Genentech Announces FDA Grants Venclexta™ (Venetoclax) Accelerated Approval for People with a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
|
|
10 Apr 2016
|
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
|
|
14 Mar 2016
|
FDA Grants Genentech’s Cancer Immunotherapy Atezolizumab Priority Review for Advanced Bladder Cancer
|
|
01 Mar 2016
|
FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Pediatric Allergic Asthma
|
|
28 Feb 2016
|
Genentech Provides Update on Two Identical Phase III Studies of Lebrikizumab in People with Severe Asthma
|
|
26 Feb 2016
|
FDA Approves Genentech’s Gazyva (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma
|
|
16 Feb 2016
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
|
neuroscience
|
12 Jan 2016
|
FDA Grants Priority Review for Venetoclax New Drug Application
|
|
11 Dec 2015
|
FDA Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval for People with a Specific Type of Lung Cancer
|
|
06 Dec 2015
|
Pivotal Phase II Study Showed Nearly 80 Percent of People with Hard-to-treat Type of Chronic Lymphocytic Leukemia Responded to Investigational Medicine Venetoclax
|
|
05 Dec 2015
|
New Results from CLL11 Study Show Gazyva® Provided People with Previously Untreated Chronic Lymphocytic Leukemia a Treatment-free Period of Nearly Four Years
|
|
21 Nov 2015
|
Updated Data Showed That Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) Helped People With a Specific Type of Advanced Melanoma Live Significantly Longer Than With Zelboraf Alone
|
|
10 Nov 2015
|
FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma
|
|
05 Nov 2015
|
Genentech to Present New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2015 Annual Meeting
|
|
08 Oct 2015
|
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
|
neuroscience
|
27 Sep 2015
|
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large Phase III Study
|
|
26 Sep 2015
|
Genentech Presents Positive Results from Pivotal Study of Investigational Immunotherapy Atezolizumab in Specific Type of Advanced Bladder Cancer at 2015 European Cancer Congress
|
|
26 Sep 2015
|
Two Positive Studies of Genentech’s Investigational Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer Presented at 2015 European Cancer Congress
|
|
08 Sep 2015
|
FDA Grants Genentech's Alectinib Priority Review for Specific Type of ALK-Positive Lung Cancer
|
|
07 Sep 2015
|
Genentech to Present Data from 15 Medicines Across Its Portfolio of Cancer Immunotherapy and Targeted Medicines During the 2015 European Cancer Congress
|
|
03 Sep 2015
|
U.S. FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
|
|
16 Aug 2015
|
Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer
|
|
12 Aug 2015
|
Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a Hard-To-Treat Type of Chronic Lymphocytic Leukemia
|
|
12 Jul 2015
|
In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
|
|
29 Jun 2015
|
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
|
|
10 Jun 2015
|
FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis
|
|
31 May 2015
|
Genentech’s Perjeta Regimen Helped People with HER2-Positive Early Breast Cancer Live Longer without Their Disease Returning or Getting Worse Compared to Herceptin and Chemotherapy
|
|
30 May 2015
|
Genentech’s Gazyva® Extended the Time People with Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease Worsening
|
|
30 May 2015
|
Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening
|
|
13 May 2015
|
Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People with Specific Type of Lung Cancer
|
|
13 May 2015
|
Genentech’s Investigational Immunotherapy MPDL3280A Reduced the Risk of Death by Half Compared with Chemotherapy in People with a Specific Type of Lung Cancer
|
|
10 May 2015
|
Pivotal Data for Genentech Medicines in Lung and Blood Cancers To Be Presented at ASCO
|
|
04 May 2015
|
Genentech Announces New STEM Education Initiative to Support South San Francisco Schools
|
|
26 Mar 2015
|
Genentech Announces Plans To Expand Hillsboro Facility
|
|
18 Feb 2015
|
FDA Grants Genentech's Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
|
|
06 Feb 2015
|
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema
|
|
03 Feb 2015
|
Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
|
|
01 Feb 2015
|
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (anti-PDL1) in Non-Small Cell Lung Cancer
|
|